Noticias de ARDX_US
Noticias del mercado
Últimas noticias sobre ARDX_US — 546 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes
Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including IBSRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on
Read Ardelyx Inc. R (41X.HM) Q4 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options
NEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
NEW YORK, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
Página 7 de 28